# Fragile X Syndrome

Confirm suspected fragile X syndrome with dedicated FMR1 CGG-repeat and methylation testing, distinguish full mutation from premutation states, and use the result to direct developmental care, symptom-targeted treatment, and cascade reproductive counseling.

**Clinical question:** How should physicians confirm fragile X syndrome, interpret FMR1 results, and organize longitudinal management and family counseling?

Updated: 2026-08-24T18:02:01.848629+00:00

## What matters in practice
- Order targeted FMR1 CGG-repeat expansion testing, with methylation assessment when needed, rather than relying on exome, genome, or typical multigene panel testing to detect fragile X syndrome. [19]
- A full mutation is defined by more than 200 CGG repeats and is usually methylated; this establishes fragile X syndrome in the appropriate clinical setting. [19]
- A premutation of approximately 55-200 CGG repeats does not establish fragile X syndrome but identifies risk for fragile X-associated tremor/ataxia syndrome and, in females, fragile X-associated primary ovarian insufficiency. [19][23]
- Mosaic repeat size or methylation can modify phenotype and should be considered when clinical function appears discordant with repeat size alone. [19]
- After molecular confirmation, prioritize developmental and behavioral intervention, assess treatable ADHD, anxiety, aggression, sleep disturbance, and seizures, and provide family-centered genetic counseling. [8][11][12][14]

## Order targeted FMR1 testing when the phenotype or pedigree is suggestive

Testing should resolve a specific FMR1-related diagnostic or reproductive question.

Order dedicated FMR1 molecular testing for unexplained developmental delay, intellectual disability, autism-spectrum features, or a family history compatible with fragile X syndrome or another FMR1-related disorder. Males may have substantial developmental delay before recognizable physical features emerge; females may have milder developmental impairment. [15]

Do not use a negative routine multigene panel, exome, or genome result to exclude fragile X syndrome. These approaches are useful when no CGG-repeat expansion is detected but clinical suspicion persists, whereas FMR1 disorders require specialized molecular testing for the CGG expansion. [19]

In an adult with intention tremor, gait ataxia, or a family history of FMR1 expansion, distinguish fragile X-associated tremor/ataxia syndrome from full-mutation fragile X syndrome by FMR1 repeat category. In a woman with ovarian insufficiency or reproductive counseling needs, determine whether a premutation is present because premutation status is associated with fragile X-associated primary ovarian insufficiency. [19][15]
- Use FMR1-specific CGG-repeat expansion testing as the first molecular test when fragile X syndrome is suspected. [19]
- Obtain a three-generation pedigree that includes intellectual disability, autism-spectrum diagnoses, tremor/ataxia, ovarian insufficiency, and known FMR1 results. FMR1-related disorders include fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency. [15][19]
- Refer confirmed or suspected expansion carriers for genetic counseling before reproductive decisions; maternal premutation alleles can expand to full mutations during intergenerational transmission. [18][22]

*FMR1 CGG-repeat categories and the clinical decision they support. [19][23]*

| FMR1 result | Interpretation | Clinical next step |
| --- | --- | --- |
| Normal: 5-44 CGG repeats | Does not indicate fragile X syndrome or increased transmission risk for fragile X syndrome. [23] | Pursue alternative etiologies if the phenotype remains unexplained. [19] |
| Intermediate: 45-54 CGG repeats | Does not establish fragile X syndrome and is not considered a risk for having a child with fragile X syndrome. [23] | Document the result and individualize counseling for family context and laboratory interpretation. [23] |
| Premutation: approximately 55-200 CGG repeats | Usually unmethylated; associated with risk for fragile X-associated tremor/ataxia syndrome and, in females, fragile X-associated primary ovarian insufficiency. [19] | Provide genetic counseling, assess the relevant adult phenotype, and discuss transmission risk. [19][23] |
| Full mutation: more than 200 CGG repeats | Usually associated with FMR1 methylation and loss of FMR1 protein expression; establishes fragile X syndrome when clinically concordant. [18][19] | Initiate syndrome-specific developmental, behavioral, and medical surveillance and offer cascade family evaluation. [14][19] |
| Repeat-size or methylation mosaicism | Mixed premutation/full-mutation or methylated/unmethylated cell lines can produce variable neurodevelopmental function. [19] | Use the complete laboratory interpretation and clinical phenotype for counseling rather than repeat count alone. [19] |

## Interpret repeat size, methylation, and mosaicism together

The actionable result is the FMR1 molecular category, not a nonspecific sequencing finding.

A definite molecular diagnosis of fragile X syndrome generally requires a full mutation exceeding 200 CGG repeats. These alleles are typically methylated, whereas premutation alleles of approximately 55-200 repeats are generally unmethylated. [19]

Use an assay that can define expansion status and address methylation when a large expansion or mosaicism is possible. Repeat-primed PCR detects and localizes AGG interruptions; Southern blot detects normal alleles, larger premutations, and full mutations and determines FMR1 promoter methylation status. [19]

Interpret phenotype by sex and molecular state. GeneReviews reports intellectual disability in essentially all males with a completely methylated full mutation and in about half of females with a full mutation; both repeat-size mosaicism and methylation mosaicism produce a broader functional range. [19]

If targeted testing shows no CGG expansion but the patient remains clinically suspicious for a genetic neurodevelopmental disorder, proceed with broader genomic evaluation rather than relabeling the patient as having fragile X syndrome. [19]
- Request the laboratory report’s repeat-size category and methylation interpretation, especially for full mutations and suspected mosaicism. [19]
- Use AGG-interruption information, when reported, as a reproductive-counseling modifier rather than as a diagnostic substitute for repeat category. [19]
- Treat a premutation result as an FMR1-related disorder risk state, not as evidence that the patient has full-mutation fragile X syndrome. [19][23]

*Testing method selection for FMR1 CGG-repeat disorders. [19]*

| Method | Useful result | Decision use |
| --- | --- | --- |
| Repeat-primed PCR | Detects CGG-repeat expansion and identifies AGG interspersions. [19] | Use for targeted FMR1 expansion detection and reproductive-risk characterization when AGG structure is relevant. [19] |
| Southern blot | Detects normal, larger premutation, and full-mutation alleles and determines promoter methylation. [19] | Use when methylation status or large-expansion characterization is needed. [19] |
| Multigene panel, exome, or genome testing | May identify alternative etiologies but is useful for fragile X evaluation only when no CGG expansion is detected and suspicion remains. [19] | Do not substitute for targeted FMR1 expansion testing. [19] |

## Organize care around developmental function and treatable comorbidities

There is no established disease-modifying clinical therapy; management targets function and comorbidity.

After DNA confirmation, arrange age-appropriate developmental and educational intervention rather than waiting for physical features to evolve. Early intervention can improve long-term cognitive outcomes, although it should not be presented as restoring normal cognitive outcome. [4][14]

At follow-up, actively identify impairment from ADHD symptoms, anxiety, aggression, and sleep problems because these are recognized medication targets in fragile X syndrome. Select medication according to the dominant treatable syndrome and reassess functional benefit and adverse effects rather than treating the molecular diagnosis itself. [8]

Assess for seizures when episodes suggest altered awareness, motor events, or unexplained regression. ADHD and epilepsy may coexist in fragile X syndrome; stimulant therapy and antiseizure treatment can be managed independently when both disorders are present. [11][12]

Use a multidisciplinary model that links the primary clinician, developmental and behavioral services, school supports, and genetics. The AAP health-supervision guidance is specifically designed for pediatric management after DNA confirmation. [14]
- Document baseline communication, adaptive function, behavior, sleep, and school or work participation; use these domains to judge whether a symptom-directed intervention is helping. [8][14]
- Evaluate suspected seizure events with a seizure-focused history and neurologic assessment; treat confirmed epilepsy with antiseizure therapy while independently addressing clinically significant ADHD. [11][12]
- Review adverse effects whenever stimulants, antidepressants, or antipsychotics are used, because these agents may suppress symptoms without correcting the underlying molecular disorder and can cause side effects. [6]

### Medication decisions

Pharmacotherapy in fragile X syndrome is symptom-directed: reported targets include ADHD symptoms, anxiety, aggression, and sleep problems. Stimulants, antidepressants, and antipsychotics may reduce symptoms but do not address the underlying FMR1 molecular defect. [6][8]
- Do not represent symptomatic psychotropic treatment as disease-modifying therapy. [6][9]
- Match medication choice to a defined target syndrome and track target behavior, function, and adverse effects at each reassessment. [6][8]

*Comorbidity-directed follow-up after confirmed fragile X syndrome. [8][11][12][14]*

| Clinical domain | Assessment trigger | Action |
| --- | --- | --- |
| Development and adaptive function | New diagnosis or loss of expected developmental progress. [4][14] | Initiate or update early-intervention, educational, and developmental supports. [4][14] |
| ADHD symptoms | Function-limiting inattention, hyperactivity, or impulsivity. [8][11] | Use standard ADHD-directed treatment planning; stimulant therapy can be managed independently from antiseizure treatment when epilepsy coexists. [11] |
| Anxiety, aggression, or sleep problems | Symptoms cause distress, safety risk, caregiver burden, or functional deterioration. [8] | Select a symptom-targeted behavioral and medication plan and monitor adverse effects. [6][8] |
| Possible seizures | Paroxysmal events, altered awareness, motor episodes, or clinical concern for epilepsy. [11][12] | Perform seizure-focused assessment and treat confirmed epilepsy with antiseizure therapy. [11] |

## Use the molecular result to counsel relatives and reproductive risk

A positive FMR1 result changes care beyond the proband.

Counsel families that fragile X syndrome results from CGG-repeat hyperexpansion in the 5′ untranslated region of FMR1, which leads to promoter hypermethylation and loss of the encoded protein in full-mutation disease. [18][21]

For a woman with a premutation, explain that the allele may expand to a full mutation during maternal transmission. Repeat length and AGG interruptions influence expansion behavior; expansion from premutation to full mutation has been documented in one generation, including a 59-repeat allele lacking AGG interruptions in a pedigree analysis. [18][22]

Offer targeted testing and counseling to biologically relevant relatives after identifying a full mutation or premutation. This can identify relatives at risk for fragile X syndrome, fragile X-associated tremor/ataxia syndrome, or fragile X-associated primary ovarian insufficiency and can inform reproductive planning. [15][19][23]

When reproductive options are being considered, refer to reproductive genetics. Preimplantation genetic testing has used FMR1 PCR-based approaches, but large GC-rich premutation and full-mutation alleles can be difficult to amplify; linked-marker approaches may be needed to reduce misclassification risk. [18]
- Classify each tested relative by the largest FMR1 allele when interpreting female results, because females have two FMR1 copies and category assignment is based on the larger repeat number. [23]
- Do not reassure a premutation carrier solely because they do not have fragile X syndrome; counsel regarding adult FMR1-associated risks and transmission implications. [19][23]
- Use reproductive genetics consultation for premutation or full-mutation carriers considering pregnancy, preimplantation testing, or prenatal diagnostic options. [18][22]

*Counseling priorities by FMR1 result. [18][19][23]*

| Result in the patient or relative | Primary counseling issue | Next action |
| --- | --- | --- |
| Full mutation | Risk for fragile X syndrome phenotype and potential family transmission. [19] | Provide syndrome management and offer cascade testing with genetics counseling. [14][19] |
| Premutation in a woman | Risk of transmission of a premutation or full mutation and risk for fragile X-associated primary ovarian insufficiency. [19][23] | Refer for reproductive counseling; discuss maternal expansion risk and reproductive testing options. [18][22] |
| Premutation in an adult with tremor/ataxia | Possible fragile X-associated tremor/ataxia syndrome. [19] | Evaluate the neurologic phenotype and coordinate neurology and genetics follow-up. [13][19] |
| Intermediate allele | Does not establish fragile X syndrome or risk for having a child with fragile X syndrome. [23] | Provide result-specific counseling and avoid diagnosing an FMR1 disorder on repeat count alone. [23] |

## References
1. Attention deficit hyperactivity disorder — adc.bmj.com — https://adc.bmj.com/content/79/5/381
2. ACMG Statements and Guidelines — www.nature.com — https://www.nature.com/collections/afebagafci
3. ACMG Standards and Guidelines for fragile X testing — www.nature.com — https://www.nature.com/articles/gim201361
4. Main Report | Genetics in Medicine — www.nature.com — https://www.nature.com/articles/gim20062z
5. Neonatal expression of human FMRP isoform corrects ... — www.cell.com — https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(26)00152-6
6. Gene therapy using an ortholog of human fragile X mental ... — www.cell.com — https://www.cell.com/molecular-therapy-family/advances/fulltext/S2329-0501(21)00115-7
7. FMR1 mutant marmosets show fragile X syndrome ... — www.cell.com — https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00979-9
8. State‐of‐the‐art therapies for fragile X syndrome — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/dmcn.15885
9. Gene Therapy for Fragile X Syndrome, Challenges, and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jgm.70049
10. A multidisciplinary approach to the management of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2788.2006.00942.x
11. 58 Attention-Deficit Disorders and Epilepsy - Oxford Academic — academic.oup.com — https://academic.oup.com/book/57972/chapter/476211974
12. Descriptive analysis of seizures and comorbidities ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/mgg3.2001
13. Fragile X‐associated tremor/ataxia syndrome: Clinical ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.21493
14. Health Supervision for Children With Fragile X Syndrome — publications.aap.org — https://publications.aap.org/pediatrics/article/127/5/994/64903/Health-Supervision-for-Children-With-Fragile-X
15. Fragile X Syndrome (Chapter 253) | American Academy of Pediatrics Textbook of Pediatric Care | Pediatric Care Online | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5779933/Fragile-X-Syndrome-Chapter-253
16. Chapter 107: The Newborn with Neurologic Findings — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5768699/The-Newborn-with-Neurologic-Findings
17. Ethical, Legal, and Social Concerns About Expanded ... — publications.aap.org — https://publications.aap.org/pediatrics/article/121/3/e693/72799/Ethical-Legal-and-Social-Concerns-About-Expanded
18. FMR1 CGG repeat expansion mutation detection and linked haplotype analysis for reliable and accurate preimplantation genetic diagnosis of fragile X syndrome - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5733830
19. FMR1 Disorders - GeneReviews® - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK1384
20. Development of Genetic Testing for Fragile X Syndrome and ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5192486
21. FMR1 premutation and full mutation molecular mechanisms ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3261276
22. Expansion of the Fragile X CGG Repeat in Females with Premutation or Intermediate Alleles - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC379237
23. How Fragile X Syndrome Is Inherited | Fragile X Syndrome (FXS) | CDC — www.cdc.gov — https://www.cdc.gov/fragile-x-syndrome/about/how-fragile-x-syndrome-is-inherited.html
24. A methylation PCR approach for detection of fragile X ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/10447261

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.